Patent ID: 7964631

Claim:
A method for the treatment of inflammatory conditions associated abnormal TNF-α activity in mammals comprising administering to said mammal a therapeutically effective amount of a compound of formula (1a) wherein R 1 , R 2 , R 3 , R 4 , R 5 , R 6 and R 8 are each independently selected from: hydrogen, halogen, hydroxy, alkyl, alkenyl, cycloalkyl, alkoxy, cyano, nitro, trifluoromethyl, aryl, heterocyclyl, heteroaryl, alkylsulfonyl, heterocyclylsulfonyl, heteroarylsulfonyl, —S(O) 2 —NH-heterocyclyl, —S(O) 2 —NH-heteroaryl, sulfonamide, —S(O) 2 —NH-alkyl, —S(O) 2 —NH-cycloalkyl, —S(O) 2 —NH-aryl, —NH—S(O) 2 -alkyl, —NH—S(O) 2 -cycloalkyl, —NH—S(O) 2 -aryl, —NH—S(O) 2 -heterocyclyl, —NH—S(O) 2 -heteroaryl, NR 11 R 12 , hydrazine and N═R′; R 7 is alkyl, —(CH 2 ) n C(O)R 9 or —C(O)NR 11 R 12 ; R 9 is hydrogen, halogen, alkyl, cycloalkyl, trifluoromethyl, OR 10 , aryl or heterocyclyl; R 10 is hydrogen, alkyl, cycloalkyl, trifluoromethyl, aryl or heterocyclyl; R 11 and R 12 are each independently selected from: hydrogen, alkyl, cycloalkyl, alkylamino, aryl, heteroaryl, heterocyclyl, —(CH 2 ) n C(O)R 9 and cycloalkylaminoalkylcarbonyl; or R 11 and R 12 , together with the N atom to which they are bonded, form a 5-, 6-, 7- or 8-membered heterocyclyl, optionally having one or more additional heteroatoms selected from: O, N and S; R′ is heterocyclyl or cycloalkyl; n is 0, 1 or 2; where alkyl or cycloalkyl is unsubstituted or substituted by one or two of the same or different groups selected from: halogen, hydroxy, alkylcarboxy, amino, cycloalkyl, alkoxy, aryloxy, alkoxylcarbonyl, arylalkoxycarbonyl, aminocarbonyl, alkylamino, dialkylamino, cycloalkylamino, cycloalkyl alkylamino, heterocyclyl alkylamino, heteroarylamino, heteroarylalkylamino, aryl, amino aryl, heteroaryl and heterocyclyl; heterocyclyl is unsubstituted or substituted by one or two of the same or different groups selected from: halogen, hydroxy, alkoxy, oxo, alkyl, cycloalkyl, cycloalkyl alkyl, aryl, hydroxyalkyl, amino, aminoalkyl, alkylaminoalkyl, heterocyclyl alkyl, heteroaryl alkyl, aralkyl, alkylheteroaryl, cycloalkylheteroaryl, formyl, alkylcarbonyl, alkoxycarbonyl, aryl alkoxycarbonyl, cycloalkylcarbonyl, arylcarbonyl, heteroarylcarbonyl, —SH, —S-alkyl, —S(O) 2 -alkyl, —S(O) 2 -aryl, alkylamino and alkylheteroarylamino; aryl is unsubstituted or substituted by one or two of the same or different groups selected from: halogen, nitro, alkyl, trifluoromethyl, alkoxy, amino, mono- or di-alkylamino, heteroaryl alkyl and aralkyl; heteroaryl is unsubstituted or substituted by one or two of the same or different groups selected from: halogen, alkyl, cycloalkyl, nitro and amino; W is S(O) m ; and m is 1 or 2; in all its stereoisomeric and tautomeric forms and mixtures thereof in all ratios, and its pharmaceutically acceptable salts and solvates.